Today: 28 February 2026
Subscribe
Browse Category

NYSE:LLY 5 February 2026 - 28 February 2026

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL shares fell 0.6% to A$153.27 Friday, ending a two-day rebound. The company disclosed a 69,497-share buyback for A$10.7 million and confirmed a new licensing deal with Eli Lilly for clazakizumab, including a $100 million upfront payment. Director Alison Watkins acquired 214 shares under a board plan. Investors are watching buyback pace and updates on the Lilly agreement next week.
20 February 2026
····
Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly reported its cancer drug Retevmo beat placebo on event-free survival in a Phase 3 trial for early-stage RET fusion-positive non-small cell lung cancer. U.S. markets are closed for Presidents Day, delaying any stock reaction until Tuesday. Lilly shares last closed at $1,040, up 0.2% Friday. Full trial data will be presented at a future medical meeting.
16 February 2026
··
Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly shares rose 0.6% to $1,044.62 after the company disclosed $1.5 billion in pre-launch inventory for its experimental obesity pill, orforglipron, ahead of an expected FDA decision in April. The company also repurchased $4.1 billion in shares in 2025 and raised its quarterly dividend. Chinese regulators approved Lilly’s mirikizumab for Crohn’s disease and ulcerative colitis. U.S. stocks slipped in midday trading.
13 February 2026
··
Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly shares rose 1.8% to $1,033.23 in late morning New York trade after Chinese regulators approved mirikizumab for Crohn’s disease and ulcerative colitis. Investors are watching a Feb. 13 ex-dividend date and an expected U.S. decision in April on Lilly’s oral weight-loss pill. Novo Nordisk shares slipped as it announced plans to launch Wegovy in vials.
12 February 2026
··
Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly shares fell 0.9% to $1,035.54 Tuesday morning after new deals in cell therapy and China drug development. The company agreed to buy Orna Therapeutics for up to $2.4 billion and struck a collaboration with Innovent Biologics. Investors weighed increased pipeline spending as competition in obesity drugs intensified. Attention turns to an upcoming FDA decision on Lilly’s oral obesity pill.
10 February 2026
··
Eli Lilly stock slides after-hours after $2.4 billion Orna deal — what to watch next for LLY

Eli Lilly stock slides after-hours after $2.4 billion Orna deal — what to watch next for LLY

Eli Lilly shares fell 1.3% to $1,044.67 in after-hours trading Monday after the company announced a deal to acquire Orna Therapeutics for up to $2.4 billion. The all-cash purchase includes milestone payments tied to clinical development. Investors are watching for updates on Orna’s cell therapy programs and regulatory decisions on Lilly’s obesity drug pipeline.
9 February 2026
·
Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.
9 February 2026
····
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.
8 February 2026
···
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly shares climbed 3.7% in after-hours trading after the FDA announced plans to restrict GLP-1 ingredients in unapproved compounded drugs. Hims & Hers shares dropped nearly 12% after being referred for a Justice Department probe. Investors are watching for details on enforcement and pricing pressure as the market reacts to moves against copycat obesity drugs.
7 February 2026
···
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY

Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY

Eli Lilly shares fell 7.8% to $1,020.84 in after-hours trading Thursday after Reuters reported Hims & Hers began selling a $49 compounded version of Novo Nordisk’s Wegovy, raising discount fears in the GLP-1 drug market. Earlier, Lilly posted a 43% jump in quarterly revenue to $19.29 billion, led by Mounjaro and Zepbound, and forecast 2026 sales above Wall Street estimates.
5 February 2026
··
Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs

Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs

Eli Lilly shares fell 6.2% to $1,038.52 Thursday morning after Hims & Hers Health announced a $49-per-month compounded Wegovy pill, undercutting branded obesity drugs. Novo Nordisk shares also dropped 6.8%. Investors focused on Lilly’s ability to protect margins as cheaper alternatives and new pricing models intensify competition. CFO Lucas Montarce warned price cuts will slow growth despite strong demand.
5 February 2026
··
1 2 3 … 12
Go toTop